G eneric pharmaceutical products play a vital role in US healthcare. Since the passage of the Drug Price Competitionand Patent Term Restoration Act in 1984 (Hatch-Waxman Amendments),' which set the rules under which generic drugs could compete with innovator products, the Foodand DrugAdministration (FDA)has approved 11,843 generic drug products. As of December2008, a total of 13,239 prescription andover-thecounterdrugs were listedas marketed in the FDA'sApproved Drug Products with Therapeutic Equivalence Evaluations ("Orange Book"),'of which 8893 (672%) were listed as "multisource" products (meaningthat generic versions are marketed). Generic drugs offera powerful approach to cost-savings for the patient-in 2008, generic drugs accounted for 69% of all prescriptions dispensed in the US, yet only 16%of all dollarsspenton prescriptions.'
All prescription and over-the-counter generic drugs marketed in the US must meet standards established by the FDA. In approving a new generic drug for marketing, the FDA concludes that it is BM Davitet at. therapeutically equivalent to its corresponding reference product (usually the innovator product, but sometimes another generic product if the innovator product was withdrawn). The FDA believes that therapeutically equivalent drug products can be substituted with the full expectation that both products will produce the same clinical response.' A generic drug is approved by the FDA if it is:
1. pharmaceutically equivalent to an approved safe and effective reference product in that it (a) contains identical amounts of the same active drug ingredient in the same dosage form and route of administration and (b) meets compendial or other applicable standards of strength, quality, purity, and identity; 2. bioequivalent to the reference product in that it (a) does not present a known or potential bioequivalence problem and it meets an acceptable in vitro standard (usually dissolution testing) or (b) if it does present such a known or potential problem, it is shown to meet an appropriate bioequivalence standard; 3. adequately labeled; and 4. manufactured in compliance with current Good Manufacturing Practice regulations.' The regulatory oversight of generic drug chemistry, manufacturing, and controls is identical to that imposed upon innovator drug products,'
Despite the wide use of generic drugs in US health care and the stringent regulatory standards governing generic drug approval for marketing, generic substitution continues to be a topic of heated debate among healthcare professionals, members of the pharmaceutical industry, consumers, and government offlcials.v" For example, there are concerns about small numbers of reported cases of breakthrough seizures or an increased seizure frequency in patients who switch from brand-name to generic antiepileptic drugs." Likewise, there are concerns about the findings of a retrospective analysis which showed that, when 975 Israeli patients were switched from Coumadin (warfarin sodium) to a generic warfarin sodium clathrate, higher doses of the generic formulation were needed to maintain previously stabilized international normalized ratio (INR) values in some patients," The American Academy of Neurology opposes generic substitution of anticonvulsant drugs for the treatment of epilepsy without the attending physician's approval.P Similarly, a report by the American Society of Transplantation recommended that generic immunosuppressive medications should be clearly labeled and distinguishable from innovator drugs and that' patients should be educated to inform their physicians of any switch to or among generic alternatives."
In particular, controversy continues to surround the FDA's methods for assessing in vivo bioequivalence between the generic and innovator products.' Some scientists and clinicians have expressed the opinion that the FDA's current bioequivalence standards may not be sufficient for certain patient populations being treated with certain classes of drugs (notably, antiepileptic drugs and/or drugs with a narrow therapeutic index), drugs that display variable absorption patterns, or drugs with nonlinear pharmacokinetics,ls.l? Some of the controversy arises from misunderstanding of the FDA's statistical methods for determining bioequivalence. s.?18 This article discusses the rationale underlying the FDA's present approach for determining in vivo bioequivalence and presents data from bioequivalence studies of generic drugs approved over a 12-year period to evaluate how the FDA's bioequivalence approach performs in ensuring that the pharmacokinetic profiles of generic drugs closely approximate those of the innovator products.
The FDA requires an applicant submitting an Abbreviated New Drug Application (ANDA) for a generic drug to demonstrate that its product is bioequivalent to the corresponding reference "listed drug."! Bioequivalence means that the generic drug and the reference drug will reach the systemic circulation at an equivalent relative rate and extent-in other words, the 2 drug products' dosage forms should produce equivalent drug concentration-time profiles in the blood. Generic applicants submitting ANDAs for systemically active solid oral dosage forms are required ,. to submit one or more bioequivalence studies in which human subjects are given the generic or reference product and drug concentrations in the blood are measured and analyzed statistically. The ANDA process as established by the Hatch-Waxman Amendments does not require generic drug manufacturers to submit nonclinical or clinical studies to establish the safety and efficacy of the active ingredient. This is because these safety and efficacy data were previously documented during the approval process for the innovator product. It is assumed that, if the active ingredient was shown to be safe and effective after it is absorbed into the bloodstream, any drug product giving rise to blood concentrations of active ingredient to the same rate and extent will produce the same effect. Bioequivalence studies are generally conducted in healthy male and female adults under standardized conditions. In some cases it is necessary to use patients for reasons of safety (eg, bioequivalence studies of oncology drug products are conducted in patients with cancer)."
Most bioequivalence studies use a 2-way crossover design.
If the drug has a long plasma half-life, it may be more suitable to use a randomized parallel study design. 20,z1 The appropriate number of subjects for a bioequivalence study can be determined based on previous knowledge of the innovator drug's pharmacokinetic variability. In general, the number of subjects should be adequate to detect a 20% difference in the measured bioequivalence parameters with 80% certainty." The FDA recommends that investigators enroll a minimum of 12 subjects 23-most studies submitted to the Office of Generic Drugs enroll from 24 to 36 sub-jects. The FDA asks investigators to conduct single-dose bioequivalence studies becauseit has beenshownthat these are more sensitive to detecting differences in formulation performance than are multiple-dose studies. 20,21,24-27 However, it is sometimes necessary to conduct a multiple-dose bioequivalence study at steady-state, for example, if the bioequivalence study is conducted in patients,"
It is recognized that a drug's maximum concentration (C max ) is an indirect measure of the rate of absorption; for example, changes in the rate of absorption influence C m •• only minimally.' In addition, Cm.x is influenced both by the blood sampling scheme and by the extent of absorption, and as a result there is a strong correlation between total area under the plasma concentration versus time curve (AVe) and C max ' Cm.x tends to be more variable than AVC in bioequivalence studies," Nonetheless, the FDA considers Cmu to be the most clinically appropriate parameter for assessingthe rate of absorption and may relate to a drug's toxicity and/orefficacy. 20, 30 Most bioequivalence studiesare conducted on the highest strength of a drug productline, unless it is necessary to use a lower strength for safety reasons. Vse of the highest strength is particularlycritical for drugs that display nonlinear kinetics becauseof nonlinear (usually capacity-limited) elimination or presystemicmetabolism, for which the extent of absorption increases more than proportionally with an increase in dose. 31, 32 For such drugs, small differences in the rate of absorption can have substantial effects on the AVe. Thus, using the highest strength,or, in some cases, the highest startingdose-so that pharmacokinetics are in the nonlinearrange-in bioequivalence studies" ensures that a generic formulation will not pass bioequivalence acceptance criteriaunless it is formulated to provide nearly the same rate and extent of exposure as the corresponding reference product. For drugs for which rate and/or extent of absorption increases less than proportionally with an increase in dose,32,34 the bioequivalence study will be most discriminating -if conducted at the lowest strength or, if only one strength is marketed,at the lowest recommended dose.
1\\'0 products are deemed bioequivalent if the 90% confidence intervalsof the geometric mean generic/innovator (or test/reference) C m •• and AVC ratios fall within the bioequivalence limits of 80-125%. 23 To obtain geometric means, the data are log-transformed prior to conducting an analysisof variance (ANOVA), then back-transformed before calculating the test/reference ratios.
The FDA asks investigators to log-transform C ma • and AVC for bioequivalenceanalysis for 2 reasons. First, the ANOVA used to conduct the bioequivalence statistics is based on a linear statistical model. However,the form of expression for AVC suggests a multiplicative model,since AVC = (F*D)/(V*Ke), where F is the fraction of drug absorbed, D the dose, V the volume of distribution, and Ke Generic Versus Innovator Drugs: Review of Bioequivalence Data the elimination rate constant.P-" For this reason, FDA statisticians concluded thateffects on AVC are not additive if the data are analyzed on the original scale of measurement. Thus, since In(AVq is equal to In(F) + In(D) -In(V) -In(Ke),logarithmic transformation of AVC allows it to be analyzed using the ANOVA, which assumes a linear statistical model. A similar argument can be made for
The second reason for log transformation is that C m •• and AVC, like much biological data, correspond more closelyto a log-normal distribution than to a normaldistribution," Plasma concentration data and derived pharmacokinetic parameters tend to be skewed, and their variances tend to increasewith the means. Log transformation generally remedies this situationand makes the variances independentof the means. In addition, skewed frequency distributions are often made more symmetrical by log transformation.
It is often incorrectly stated thatbecausethe widthof the bioequivalence limits is 80-125%, the FDA allows C max and AVC to vary by -20 to +25% between products. In fact, such a large absolutedifference between test and reference bioequivalence parameters will virtually always result in failure to meet bioequivalence limits.The statistical approach used by the FDA to analyze bioequivalence study data is designed to minimize the risk in situations where the patient is switched to a generic version of a medication that he or she is currently taking.
The 2 one-sidedtests procedure is used to analyzebioequivalence parameter data." One test verifies that the bioavailability of the generic productis not more than 20% less than that of the innovatorproduct. The other test verifies that the bioavailability of the innovator product is not more than 20% less than that of the generic product. The use of the 20% criteria is based on a decision by FDA medical experts that, for most drugs, a ±20% difference in the concentration of active ingredient in the blood will not be clinically significant," Numerically, this is expressedas a limit of 80% on the test mean/reference mean for the first statistical test and a limit of 80% on the reference mean! test mean for the second statistical test. Since by convention, all data are expressed as the test/reference ratios for C max and AVC, the limit expressed in the second statistical test becomes the reciprocal of 80%, which is 125%. As a result, the bioequivalencelimits are 80-125%. Both C max and AVC must meet the bioequivalence limits.The determination of bioequivalence using this approach is termed average bioequivalence."
Use of the average bioequivalence method ensures that the rate and extent of drug absorption from a genericproduct will differ very little from that of its innovatorcounterpart. If the true average response of the generic product in the population is close to 20% below or 25% above the innovator average response, one or both of the 90% confi-
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The Annals of Pharmacotherapy • 2009October, Volume 43 • 1585 dence interval limits is likely to fall outside of the bioequivalence limits, and the product will fail the bioequivalencetest ( Figure I ). In fact, it has been suggested that, using the 2 one-sided tests procedure, when the mean C ma • and AVC responses of 2 drug products differby more than 12-13%, they are unlikely to meet the bioequivalence limits of 80-125%. 21 The current practiceis to carry out the 2 one-sided tests at the 0.05 levelof significance. Sincea 5% statistical error is allowedat both the upper and lower bioequivalence limits, the combined total error is 10%, generating the 90% confidence interval of 80-125%. The practice of carrying out the 2 one-sided tests at the 0.05 level of significance ensures that, if the average bioequivalence parameters of the generic productare truly 20% less or 25% greater than corresponding innovatorvalues, the generic will have less than a 5% chanceof beingapproved as equivalent."
It is logicalto ask why bioequivalence data are not analyzed by a 2-tailed test at the conventional level of pless than 0.05, as opposed to performing 2 one-sided tests. In fact, in the early years of the FDA's generic drug review program,bioequivalence statistics were conducted using2tailed hypothesis testing at the 5% level of significance. The null hypothesis was that the means of the 2 formulations did not differ significantly. It was found that this approachresulted in a problem with the power of the test, [36] [37] [38] [39] Products that showed nearly the same means, with very small variance,could show a significant difference and be rejected. Alternatively,products that showed large differences with a large variance could show a nonsignificant difference and be deemed equivalent, To overcome these problems,the FDA beganto use a power approach,which added the additional requirement that the power of the test for no difference had to be sufficiently large(80%). However, therewere additional problems withthe powerapproach.
For example, if the within-subjectvariability was high, it would not be possible to conclude equivalence no matter what the difference between test and reference products was, becausein this situation, the estimated power was less than 80%. 37, 39 The problems with these approaches arose from the fact that the t-test of the hypothesis of no difference does not assess the evidence in favor of the conclusionthat the test and reference means are equivalent, but rather assesses the evidence in favor of a conclusion that the test and reference meansare different, whichis not the question of interest in the bioequivalence analysis. 37, 39 The 2 one-sided tests procedure currently used by the FDA resolves the problems of hypothesis testing and assumes that test and reference products within 20% of each other with respect to C max and AVC are bioequivalent."
The FDA does not ask ANDA applicants to use statistical procedures to compare test and reference time to C ma • (t",a.) values. Although theoreticallya relatively sensitive measure of absorption rate, t",a. is thought to have shortcomingsas an indirectmeasureof the rate of drug absorption. 40 ,41 For example, ANOVA analysis cannot be applied to tma.; unlike C m .. and AVe, which are continuous vari-" ables, tma. is a discrete measuredependenton frequency of blood sampling." In addition,most pharmacokinetic studies typicallyemploy irregularsamplingschemes to collect t",a. data; as a result, these data are not routinely amenable to proper statistical evaluation." For these reasons, the FDA has decidednot to imposebioequivalence acceptance criteria on the parameter tma.. 20 Nonetheless, the FDA believes that t.n.. should be consideredin bioequivalence decision-making and routinely examines t",a. data in bioequivalence studies as supportive data to verify that the test and reference products have the same rate of absorption.r' 
Methods

COMPARING GENERIC AND INNOVATOR PRODUCT
BIOEQUIVALENCE PARAMETERS
We hypothesized that,over a long periodof time,generic drug product average bioequivalence parameters will differ very little from those of their corresponding innovator counterparts becauseof the rigors imposed by the average bioequivalence statistical approach and bioequivalence limits of 80-125%. To test this hypothesis,we collected a set of bioequivalence parameter data from all acceptable single-dose bioequivalence studies of generic solid oral dosage form drug products approved from 1996 through 2007 (12 y). This time period Was selectedbecausethe Office of Generic Drugs began archiving ANDA reviews electronically in 1996,thus facilitating data collection (prior to 1996,paper copies of all ANDA reviews were stored in file rooms).Studiesenrolled both male and female sub-
Fail Fail Pass jects; in all studies, the test or reference product was administered following an overnight fast. All bioequivalence studies wereacceptable in that the bioequivalence parameters metthe FDA'sbioequivalence limits.
BIOEQUIVALENCE DATA ANALYSIS
The original pharmacokinetic and statistical calculations for the in vivo bioequivalence studies were performed by scientific reviewers from the Division of Bioequivalence, Office of Generic Drugs, using SAS (SAS Institute,Inc., Cary, NC). For the purpose of this retrospective study, these data were collected using Access (Microsoft Corp., Redmond, WA). Data analyses were conducted in Excel (Microsoft Corp., Redmond, WA) and S-Plus (TIBCO Software, Inc.,PaloAlto,CA).
BIOEQUIVALENCE PARAMETERS EVALUATED
Bioequivalence parameterdata included the test/reference geometric mean ratios (point estimates) for emax, AUC o.!, and AUC., from each of these studies in our dataset. The parameterAUCo.! is the area under the drug plasma concentration versus time curve from time 0 (immediately after dosing) until the last study samplingtime (t); AUC., is AUCu-! extrapolated to infinity. The FDA Office of Generic Drugs deems a bioequivalence study acceptable only when the 90% confidence intervals of the test/reference geometric mean ratios for all 3 parameters meet the 80-125% bioequivalence limits. All bioequivalence studiesevaluated for this investigation were acceptable to the Office of Generic Drugs in that the 90% confidence intervals of the test/reference geometric mean ratios for all 3 parameters met bioequivalence limits. Until recently, generic drug applicants were not required to submit unacceptable bioequivalence studies to ANDAs. As of July 15,2009, ANDA applicants are required to submit data from all bioequivalence studies on a drug product formulation submitted for approval,"
To determine how welleach generic drug (test) product performed compared with itscorresponding innovator (reference) product, we performed 2 typesof comparisons.
COMPARING GENERICIINNOVATOR GEOMETRIC
MEAN RATIOS
For the firstcomparison, we firstobtained the geometric meantest/reference ratiofor c....., AUCo of the difference between the average InC maxTEST and average InC maxREF • In practice, in the Officeof Generic Drugs, the geometric mean ratios are calculated using ANOVA, general linearmodels procedure (PROC GLM)available in SAS. 46 The ESTIMATE statement in SAS PROCGLM is used to obtain estimates for the adjusted differences between testandreference treatment means. The antilogarithm of the ESTIMATE gives thetest/reference ratio in thenormal scale.
Thus, the equation for calculating a geometric mean ratio for the parameterC;.. in a bioequivalence study is as follows:
geometric meanratiofor C max = e DillCmax where DiffCmax=
The same procedure is used to calculategeometric mean ratiosfor AUCo-! and AUCoo.
For the first comparison, we determined the C ms . , AUCu-!, and AUCoo geometric meanratiosfromeach of the acceptable bioequivalence studies and averaged thesegeometric mean ratios.
COMPARING ABSOLUTE DIFFERENCES BElWEEN
GENERIC ANDINNOVATOR GEOMETRIC MEANS
For the secondcomparison, we determined the absolute differences between the test and reference C max , AUC o.!, and AUC.,geometric means. The geometric mean is the antilogarithm of the average of the In-transformedC ms . , AUC o.!, and AUCoo values for the test and reference products. We compared the magnitudeof these differences to see how close the generic drug productgeometric means wereto the innovator drug product geometric means.
COMPARING IMMEDIATE·RELEASE AND
MODIFIED-RELEASE PRODUCTS
We compared data from bioequivalence studies of immediate-release (IR) and modified-release (MR) solid oral dosage forms.The term modified-release encompasses extended-release (alsoreferred to as sustained-or controlledrelease) and delayed-release products.
Results
We collected data from a total of 2070 acceptable single-dose bioequivalence studies of solid oral dosage forms, conducted from 1996to 2007.The numberof subjects used in thesestudies ranged from 12to 170. The geometric mean(test/reference) ratios for 2070bioequivalence studies of solid oral dosage form generic drugs approved duringthat time averaged 1.00 for all 3 bioequivalence pa-
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The Annals ofPharmacotherapy • 2009October. Volume 43 • 1587 rameters ( Table I) . The average percent differences between the test and reference geometric means for C m s , ' AUC o . t, and AUCcc were 4.57 ± 3.59%, 3.23 ± 2.74%, and 3.17 ± 2.69%, respectively ( Table 2) . We determined the average geometric mean (generic/innovator) ratios and mean differences between generic and innovator bioequivalence measures for IR and MR products to compare performance of the 2 types of oral dosage forms. Our data set consisted of 1788 (86%) and 282 (14%) bioequivalence studies conducted for IR and MR products, respectively.Geometric mean ratios in the bioequivalence studies of IR products averaged 1.00 for C m s x s AUC o . t, and AUC.., respectively ( Table I) . Results were similar for the bioequivaJence studies of MR products; the average of all geometric mean ratios was 0.99 for C ma . , and 1.00 for AUC o . t and AUCee, respectively. For MR products, the mean difference between the generic and innovator geometric mean ratios was slightly greater than for IR products ( In general, differences between generic and innovator bioequivalence parameters were somewhat lower for IR products than for MR products (Figure 3 ). For C m s . , the generic and innovator differed by less than 10% in 92.3% and 87.5% of the studies for IR and MR products, respectively (Table 3) . For AUC o _ t, the generic and innovator differed by less than 10% in 97.8% and 96.1 % of the studies for IR and MR products, respectively (Table 3) .
We recognized that the tables and figures, which represent the distribution of mean ratios and differences, do not consider sample size variability among the studies. For example, the larger the sample size, the better the estimate of mean difference or ratio. Since there is a relationship between sample size and the accuracy of the estimate of the mean difference or ratio, the within-subject variability associated with each drug product is an important variable that should be taken into account. Different drug products can vary significantly in the degree of variability, confounding the relationship between sample size and the accuracy of the estimate. To address this concern, we created scatter plots of the percent difference between means and sample size for each of the parameters. Percent difference , was used to normalize for different plasma concentration' units used in the different studies, as well as different bioavailabilities of the drug substances. The resulting scat- ter plots did not appear to show a relationship between samplesize and the difference between means. Additionally, distribution plots of effect sizes for the parameters were created. Effect sizewas calculated as the difference betweengeometric mean test and referencevalues divided by the standard deviation of the reference value, (mean.; -meanreference)/SDreferen<e' The distribution of effect sizesdid not suggestany directional bias.This is consistent withthefactthatthebioequivalence studies evaluated forthis paper are for different drugs and different formulations and are conducted by different investigators. As such,it would be Generic Versus Innovator Drugs: ReviewofBioequivalence Data highlyunlikelythat test productswould consistently show greater or lessbioavailability thanreference products.
Discussion
Our findings confirm the results of 2 similar FDA reviews comparing bioequivalence measures. A review of 224 in vivo bioequivalence studies in ANDAs approved shortly after the Hatch-Waxman amendments were passed, from 1984 to 1986, found that the average percent difference between mean AVes of the innovator drug and generic drug was about 3.5%.47 A review of 127 in vivo bioequivalence studiesof generic drugs approvedin 1997 found mean percent differences between the innovator and generic products of 4.29%,3.47%, and 3.25% for C m •• , AUCO-" and AUC.., respectively." We evaluated plausible reasons why, in 2.4% of the studies, the generic AUC o ., varied from the reference AUC o ., by more than 10%. For this evaluation, we considered AUC o " to be the most meaningful of the 3 bioequivalence parameters. It is well established that AUC is less variable than C m •• ,29 which depends upon the sampling schedule and varies (particularly for IR products) with the magnitude of AUC.5 Of the 2 total exposure parameters, AUC o ., is considered a more accurate representation of systemic exposure thanAUCee, as AUC o ., is determined by experimental measurement, whereas a portionof AUC.. is derived by mathematical extrapolation,"
The 49 studies for which the generic AUC o ., differed from the reference by more than 10% were of 39 different drugs from a variety of drug classes.None is considered a narrow therapeutic index drug; in addition, none of these was an antiepileptic or immunosuppressant drug. We surveyed the formulations of these products to determine whetherthe test and reference products contained differing amounts of excipients knownto affect bioavailability, such as alcohol sugars," polysorbate-Bu," or~-cycl odextrins. 52 We wereunableto identify any properties of the excipients used that could result in differences in bioavailability between the test and reference products.
However, mostof these39 drugs werepreviously identifiedas highly variable drugs,that is, as havinghigh withinsubjectvariability (~30%) in the bioequivalence measures AUC and C max ' In general,thesedrugs are characterized as having pooraqueous solubility, having loworalbioavailability,and/orundergoing extensive first-pass metabolism. A description of these highly variable drugsubstances, including mechanism of action, physicochemical properties, and pharmacokinetic characteristics, has beenpublished."It is difficult for highlyvariable drugsand drugproducts to meet the standard bioequivalence criteria usinga reasonable number of study subjects. Thus,forgeneric highly variable drugs, the FDA presently recommends thatANDAapplicants increase the numberof study subjects, use a group-sequential study design, or usea reference-scaled average bioequivalence approach. In thereference-scaled approach, the bioequivalence criterion is scaled to thewithin-subject variability of thereference productin a crossoverbioequivalence study, together with a constraint imposedon the geometric mean ratiobetweenthe test and reference products. The reference-scaled approach is supported by the pharmaceutical science community because it is believed thathighly variable drugsgenerally havea widetherapeutic window; in otherwords,despite highvariability, these products havebeendemonstrated to be bothsafe andeffective,"
Our retrospective analysis has the advantage that it encompassed results of a large number of acceptable bioequivalence studies (2070) submitted to the Agencyin support of generic drug products approved over a long time period (12 y). Nonetheless, information is lacking about some factors that could influence the variability of the data collected. First, it is not possible to compare the variability of the data from acceptablebioequivalence studies in our study with the variability of data from unacceptable bioequivalence studies conducted duringthe same time period. This is because,untilrecently, ANDA applicants were not required to submitall bioequivalence studies conducted on the final to-be-marketed formulation. The Agencydid not begin to receive results from an appreciable numberof unacceptable bioequivalence studies until after a Pharmaceutical Sciences Advisory Committee meeting in 2000, at which ANDA applicantswere urged to submit the results of all bioequivalence studieson the final genericdrug forrnulations." Thus, although the Office of Generic Drugs has received some data from unacceptable bioequivalence studies, we presently have no way of determining whether thesedata are from all unacceptable bioequivalence studies or representa biased sample. Since ANDA applicantsare now required to submit data from all bioequivalence stud- ies on a drug product formulation submitted for approval." it will be possible for the FDA to conduct comparative analyses of acceptable and unacceptable bioequivalence studydata.
A second factor possibly influencing the variability of the data in our study is that, for many of the studiesevaluated, the majorityof subjects were healthy individuals between the ages of 18andro, Until 2000,when theFDAfirst posted itsGuidance for Industry on Bioavailability and Bioequivalence Studies for OrallyAdministered Drug Products, bioequivalence studies on genericdrug productsgenerally enrolled exclusively healthy young, male subjects. FDA Guidancefor Industry now recommends that investigators enroll in bioequivalence studies individuals representative of the general population, taking intoaccount age,sex,andrace, with an emphasis on (1) recruiting similar proportions of males and females in the study and (2) including as many subjects of ro years or olderas possible." Thus,manyinvestigators now enroll in bioequivalence studies similar proportions of males andfemales and subjects from various ethnicities. However, very few studies include subjects aged 60 years or older. In addition, bioequivalence studies conducted at clinical sites in some Asian countriescontinue to enroll onlymales of one race. It is not known what effect further in-creasing the diversity of the study population wouldhaveon thedistribution of variability in c.....x and Ave ratios.
One factor that could support the validity of the FDA bioequivalence approach wouldbean analysis of postmarketing safety and efficacy data on approved generic drug products. Futureresearch on the performance of the FDA's generic drug programcould involve an evaluation of Med-Watch generic drugdata submitted to the FDA. It shouldbe emphasized that the FDA has access to all safety data obtainedduring the bioequivalence study. Scientific reviewers from the Office of Generic Drugsevaluate the adverse event data from the test and reference products. If a reviewernotices a difference in the incidence of adverseevents during the study, the ANDAis forwarded to an FDA medical officer for a clinical consult. Bioequivalence studies aredeemed unacceptable if there is a clinically significantdifference between test and reference products with respect to adverse events. Thus,for all thestudies compared in thisretrospective analysis, the nature and severityof adverse events experienced by the subjects werecomparable in the testand referenceproduct treatment groups.
Our evaluation of 12yearsof acceptable bioequivalence studies suggests that,overall,pharmacokinetic measures of .drug rate and extent of exposure differ very little between innovator drugsand corresponding generic drugs approved for marketing-in the US. Consequently, the FDA expects that switching to a generic drug from the innovator drug will not affect clinical outcome. Findings from several clinical studiesof switchesfrom innovatorto corresponding generic products support this hypothesis. In a prospective, observational study,a health maintenanceorganization that formerly dispensed only Coumadin monitored 182enrollees.for8 months prior to and 10 months after a switch to a generic warfarin sodium tablet product and found no significant changes in INR, frequency of INR monitoring, numberof dose changes,and rate of thrombic and hemorrhagicevents." In an observer-blinded,crossover study, no significant difference in INR or adverse event profiles was observed in patients who had received Coumadin for at least 2 months and were randomized to receive 28-day periodsof generic warfarin sodium tablets for 1 period followed by Coumadin for 2 periods or Coumadin for 1 periodfollowed by generic warfarin sodium tablets for 2 periods." A recent study of hospital admission rates for cardiovascular diseases among 49,673 users of brand-name and generic metoprolol did not reveal any differences in the incidence rates of seriouscardiovascular events between the brand-name and generic group after confounder adjustment.P A recent aggregate metaanalysis of 47 studies compared 8 subclasses of generic and innovator cardiovascular drugs;the analysis concluded that the generic and innovator drugs were similarin nearly all clinical outcomes, including vital signs,clinicallaboratory-values, adverseevents,and healthcare system utilization." Clinical equivalence was noted in 100% of~-bl ock ers, 91% of diuretics, 71% of calcium channel blockers, 100%of antiplatelet agents, 100%of statins, 100%of angiotensin-converting enzyme inhibitors, and 100% of ablockers. In this same study, among narrowtherapeutic index drugs, clinical equivalence was reported in 100% of class 1 antiarrhythmic agentsand 100% of warfarin. .Nonetheless, substitution of generic antiepileptic, immunosuppressant, and narrow therapeutic indexdrugscontinues to be a controversial subject. For a number of reasons, the FDA'sposition is that less-expensive generics can be substituted for the innovator (more-expensive) drug products, regardless of the indication.First, as shown by this study and previous retrospective studies, the rate and extentof drug absorption differvery littlebetween innovator drugs and corresponding generic drugs approved for marketing in the US. Thus, the FDA believes that,considering the variability of the overall clinical response, any contribution of generic substitution to varying plasmaconcentrations is negligible.For example, high variability in antiepileptic drug plasmaconcentrations has been reported in patientson continuous treatment. 60 ,6\ In addition, coadministration of certain drug products withoutdose adjustment (as recommended according to product labeling) and
Generic Versus InnovatorDrugs:ReviewofBioequivalence Data lack of patientadherence may cause changes in drug plasma concentrations exceeding any smallchanges that might resultfrom generic substitution."
Another important reason why the FDA believes that approvedgeneric drugs may be substituted for their corresponding innovatorproductsis that ANDA applicants are required to submitthe same drug substance and drug product CMC (Chemistry, Manufacturing, and Controls) information for approval as NDA applicants." Both NDA and ANDAapplicants mustsubmit to theFDA a full description of the drug substance,including its physicaland chemical characteristics and stability; the method of synthesis (or isolation) and purification of the drug substance; the process controls usedduring manufacture and packaging; and specifications needed to ensure the identity, strength, quality, and purity of the drug substance. Both NDA and ANDA applicantsmust submitto the FDA a listof all components used in the manufacture of the drug product (regardless of whether they appearin the drug product); specifications for eachcomponent to ensure itsquality; product design anddevelopment, manufacturing, and process control; and specifications needed to ensure the identity, strength, quality, purity (including impurities), and bioavailability of the drug product.The FDA does not approve NDA and ANDAproducts if the Agency determines that the submitted CMC informationis notacceptable.
Anotherreason that the FDA believes that generics can be safely substituted for the corresponding innovator products is that, throughout the lifetime of a generic product, the FDA will carefully investigate any reports of therapeutic inequivalence and take regulatory action if necessary. Two recent cases illustrate this process. In the first case, due to reports of clinical concerns aboutthe quality of various levothyroxine sodiumtablets (whichmany considerto be a narrowtherapeutic indexdrug),the FDA initiatedactions to narrow the potency specifications for alilevothyroxine sodium tablet products." The United States Pharmacopeiasubsequently endorsedthe new narrow potency specifications for this product." These narrow potency specifications, now required by the FDA, ensure that both generic and innovator levothyroxine sodium tablets will maintain potency, and consequently clinical effect, throughout the approved shelf life.
In the second case, due to claims that a generic version of cycIosporine was not bioequivalent to the corresponding innovatorproduct under some conditions of use, the FDA promulgated a new bioequivalence regulation. A firm that manufactured a generic cyclosporine oral solution had conducted a study showing that its product was not bioequivalent to the corresponding innovator product when both were administered in apple juice (the products were bioequivalent when administered in water) but did not inform the FDA of this study finding until 2 years after approval," To prevent this situation from happening again,
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The AnnalsofPharmacotherapy • 2009 October, volume43 • 1593 the FDA immediately took steps to promulgate a new rule requiring ANDA applicants to submit all bioequivalence studies on the final to-be-marketed formulation, whether the studies meet or fail to meet bioequivalence acceptance criteria. The new rule, Requirements for Submission of Bioequivalence Data, was issued in final form in 2009. 45 The new rule amends the Code of Federal Regulations (CFR) Bioavailability/Bioequivalence Regulations of 21 CFR Part 320 to require an ANDA applicant to submit data from all bioequivalence studies that an applicant conducts on a drug product formulation submitted for approval, including studies that do not meet the specified bioequivalence criteria: The final rule also amends portions of 21 CFR Part 314 (Applications for FDA Approval to Market a New Drug) Subpart C, Abbreviated Applications. All bioequivalence studies submitted on the same drug formulation as that submitted for approval must be submitted to the FDA either as a complete study report or a summary report of the bioequivalence data. The term same drug productformulation means that the formulation of the drug product submitted for approval and any formulations that have minor differences in composition or method of manufacture from the formulation submitted for approval are similar enough to be relevant to the Agency's determination of bioequivalence. Thus, this new rule will provide additional assurance that generic products are therapeutically equivalent to their corresponding innovator counterparts by allowing the FDA to make regulatory decisions based on all bioequivalence data obtained for a given product.
The above examples show that the FDA takes very seriously claims of therapeutic inequivalence of generic drug products, including antiepileptic, narrow therapeutic index, and immunosuppressant drugs, and will take necessary steps to investigate such claims and modify regulatory requirements. The FDA continues to regulate generic drug products even after the initial approval process to ensure therapeutic equivalence to the corresponding innovator products.
A final consideration supporting generic substitution is the fact that generic drugs are generally considerably less costly than the corresponding innovator products. The use of generic drug products has resulted in savings of $734 billion to the US healthcare system over the past decade, with $121 billion of these savings achieved in 2008 alone. 66 One study estimates that the enactment of legislation preventing a pharmacist from substituting generic for innovator counterparts of drug classes such as antiepileptics, immunosuppressants, and antipsychotics would result in increased drug costs to commercial payors by $17.5 billion, Medicaid by $6.2 billion, and consumers by $5.3 billion over 10 years."
As the new administration of the US government seeks to cut health costs, an attractive approach is to initiate a regulatory pathway for approving generic versions of biologic drug products. Notably, several countries have set a precedent for such approvals." The European Union (EU) opened up a regulatory pathway for "biosimilars" in 2005, and since then its European Medicines Agency has approved 13 such drugs. A number of the European guidelines have been adopted in Australia, and Japan this year issued its own guideline for the regulation of biosimilars. The World Health Organization and Health Canada have recently issued draft guidelines that generally follow the EU model. In the US, however, the pathway for approval of "follow-on" biologics is stalled, in part because the law that governs licensing of biologic products does not contain a provision for follow-on biologics. The issue is currently before the US Congress. Discussion in Congress so far focuses on a number of key issues that must be addressed in any approval system for follow-on biologics, including duration of market exclusivity for the innovator product, scope, data requirements, immunogenicity interchangeability, trade names, and economic considerations," One important issue under debate is how much discretion the FDA should have to determine requirements for approval of follow-on biologics.
To summarize, the FDA's generic drug policies are designed to approve high-quality generic drug products that ,. are therapeutically equivalent to their innovator counterparts. Both generic and innovator products must meet the same FDA standards for manufacturing and quality. Despite concerns about the rigor of FDA's bioequivalence testing methods, the FDA's record shows that its bioequivalence approach works quite well to ensure that drug plasma concentrations achieved after dosing with generic drug products differ very little from drug plasma concentrations observed after dosing with the corresponding innovator counterparts. In our survey of generic drugs approved over a 12-year period, the average difference in the rate and extent of drug absorption between generic and innovator products was 4.35% and 3.56%, respectively. In addition, in nearly 98% of the bioequivalence studies conducted during this period, the extent of drug absorption from the generic product differed from that of the innovator product by less than 10%. These findings emphasize that the bioequi valence statistical criteria used for generic drug approvals effectively preclude large differences between products that the FDA deems as bioequivalent.
The robust performance of bioequivalence testing in generic drug approvals over many years lends strong support to the FDA's belief that health professionals can substitute drug products determined to be therapeutically equivalent with the full expectation that the generic product will produce the same clinical effect and safety profile as the innovator product. PhD EXTRACfO TRASFONDO: En los EstadosUnidos,los manufactureros que buscan aprobaci6n para mercadear una droga genericatienenque someterdatos que demuestren que la formulaci6n genericaproveela misma velocidad y extensi6nde absorci6n que (es bioequivaiente a) la droga innovadora. Por tanto, la mayorfa de las drogasde administraci6n oral en los Estados Unidoses aprobadaa base de resultados de uno 0 mas estudiosclfnicos de bioequivaiencia.
Barbara M Davit
OBJETIVOSDELESTUDIO: Evaluarc6mo comparanlas medidasde bioequivaiencia de drogasgenericas aprobadas en losEstados Unidos durante un perfodo de 12aiios,conaquellas de suscorrespondientes contrapartes innovadoras. '
MtroDOS: Este analisisretrospectivo compare las medidasde bioequivalenciade drogasgenericase innovadoras en 2070estudioscIfnicos de bioequivaiencia de dosis unitariade drogas genericas de administraci6n oral aprobadaspor la Administraci6n de Alimentosy Drogasde los EstadosUnidosde 1996a 2007 (12 anos).Lasmedidasde bioequivalenciaevaiuadas fueronconcentraci6n maximade la droga en plasma (C_) y area bajo la curvade c~mcentraci6n.de la droga versustiempo (AUC), representando la velocidad y extensionde absorci6nde la droga, respectivamente. Se determin6la Cgenerica/innovadora y la raz6n de las medias geomenicas (GMRs) delarea bajola curvaen cadaestudio de bioequivaiencia que us6 de 12a 170sujetos.La GMRs de los 2070 estudios fue promediada. Ademas.ladistribuci6n de lasdiferencias entre las mediasde drogasgenericas y las mediasde drogasinnovadoras fue determinada tanto para C..... como para AVe. RFSULTAOOS: La media± DE. (Desviaci6n Estandar) de la GMRs de los 2070 estudiosfue 1.00± 0.06 para Cy 1.00± 0.04 para AUe. La diferencia promedio en Cy AVC entredrogasgenericas e innovadoras fue435% y 3.56%,respectivamente. Ademas, en casi98%de losestudios de bioequivaiecia lIevados a cabo duranteeste periodo,el area bajo la curva (AUC)de la droga genericase diferenci6 del de la droga innovadora por menosde 10%. CONCLUSIONF.'J: Los criterios usadosparaevaluarlos estudiosde bioequivaiencia dedrogasgenericas apoyan el objetivo de la Administraci6n de Alimentos y Drogasde aprobarformulaciones de drogasgenericas que son terapeuticamente equivalentes a sus contrapartes innovadoras, REsUME CONTEXTE: Aux USA.les fabricants qui cherchent aintroduire un medicament generique sur Ie marchedoiventdemontrerque la forme generique presente les memesvitesseet capacite d'absorption que (est bioequivalente a) la formeoriginalemarqueedu produit.Ainsi,aux USA,la plupartdes medicaments generiques administrables oralement sontapprouves sur la base d'une ou plusieurs etudesc1iniques de bioequivalence. 
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